Cooperation with recurrent mutations that occur early in tumor progression, maybe most prominently the p53 tumor suppressor, may further promote Notch-specific effects on EMT and thus enhance aggressive properties [32], as well as promote drug resistance, as demonstrated for cetuximab in HNSCC [35]. This evidence concerns the gene TP53 and neoplasm.